Braczynski Anne K, Schulz Jörg B, Bach Jan-Philipp
Department of Neurology, RWTH Aachen University Hospital, Aachen, Germany.
Jülich Aachen Research Alliance (JARA) - JARA-Institute Molecular Neuroscience and Neuroimaging, FZ Jülich and RWTH University, Aachen, Germany.
J Neurochem. 2017 Dec;143(5):467-488. doi: 10.1111/jnc.14207. Epub 2017 Oct 16.
Vaccination therapies constitute potential treatment options in neurodegenerative disorders such as Alzheimer disease or Parkinson disease. While a lot of research has been performed on vaccination against extracellular amyloid β, the focus recently shifted toward vaccination against the intracellular proteins tau and α-synuclein, with promising results in terms of protein accumulation reduction. In this review, we briefly summarize lessons to be learned from clinical vaccination trials in Alzheimer disease that target amyloid β. We then focus on tau and α-synuclein. For both proteins, we provide important data on protein immunogenicity, and put them into context with data available from both animals and human vaccination trials targeted at tau and α-synuclein. Together, we give a comprehensive overview about current clinical data, and discuss associated problems.
疫苗接种疗法是治疗神经退行性疾病（如阿尔茨海默病或帕金森病）的潜在选择。虽然针对细胞外淀粉样β蛋白的疫苗接种已开展了大量研究，但最近的重点已转向针对细胞内蛋白tau和α-突触核蛋白的疫苗接种，在减少蛋白积累方面取得了有前景的结果。在本综述中，我们简要总结了从针对淀粉样β蛋白的阿尔茨海默病临床疫苗试验中汲取的经验教训。然后我们将重点放在tau和α-突触核蛋白上。对于这两种蛋白，我们提供了关于蛋白免疫原性的重要数据，并将其与针对tau和α-突触核蛋白的动物和人类疫苗试验所获得的数据相结合。我们共同给出了当前临床数据的全面概述，并讨论了相关问题。
